Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Pharmaceuticals Inc.

Division of Lupin Ltd.
www.lupinpharmaceuticals.com

Latest From Lupin Pharmaceuticals Inc.

Reddy’s, Lupin And Mylan Clear Two Vimovo Patents From Path

Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.

Intellectual Property Legal Issues

The Post-Shutdown Quality Lowdown

Quality oversight activity began ramping back up after the partial US government shutdown, even as EU oversight activities entered into a Brexit-related slowdown.

Compliance Manufacturing

CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due

The European Medicines Agency’s key scientific committee, the CHMP, is deciding whether a raft of new products, including Eli Lilly’s galcanezumab, should be approved for sale across the EU. Sarepta’s appeal of the CHMP’s earlier rejection of its marketing application for Exondys is also slated for a decision.

Europe Drug Review

CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due

The European Medicines Agency’s key scientific committee, the CHMP, is deciding whether a raft of new products, including Eli Lilly’s galcanezumab, should be approved for sale across the EU. Sarepta’s appeal of the CHMP’s earlier rejection of its marketing application for Exondys is also slated for a decision.

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Cardiovascular
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lupin Ltd.
  • Senior Management
  • Vinita Gupta, CEO
    Paul McGarty, Pres.
  • Contact Info
  • Lupin Pharmaceuticals Inc.
    Phone: (866) 587-4617
    Harborplace Tower, 111 S.Calvert St.
    21st Fl.
    Baltimore, MD 21202
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register